scispace - formally typeset
E

Elsebeth Lynge

Researcher at University of Copenhagen

Publications -  484
Citations -  19048

Elsebeth Lynge is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Population & Breast cancer. The author has an hindex of 59, co-authored 461 publications receiving 17055 citations. Previous affiliations of Elsebeth Lynge include Statens Serum Institut & Karolinska Institutet.

Papers
More filters
Journal ArticleDOI

Risk stratification of women with false-positive test results in mammography screening based on mammographic morphology and density: A case control study

TL;DR: All four methods, capturing either mammographic morphology or density, could segregate women with false-positive mammography screening results according to their risk of future breast cancer - using already available screening mammograms.
Journal ArticleDOI

Background and design of a Danish cohort study of workers in phenoxy herbicide manufacture.

TL;DR: The data collection has shown that ATP provides a valuable data source for control of company records in Denmark, and special attention was given to soft tissue sarcomas and malignant lymphomas, which are the diagnostic groups associated with exposure to phenoxy herbicides in the Swedish case-control studies.
Journal ArticleDOI

Incidence of the upper respiratory and digestive tract cancers and consumption of alcohol and tobacco in Denmark.

TL;DR: It is shown that the predicted incidence is strongly dependent on the distribution of smoking and drinking, and that the existence of a group with heavy consumption of tobacco and alcohol could be responsible for very high incidences of these cancers in the near future in Denmark.
Journal ArticleDOI

Benefit‐to‐harm ratio of the Danish breast cancer screening programme

TL;DR: The objective of the study was to estimate the benefit‐to‐harm ratio of breast cancer screening in Denmark, and it was estimated that 2–3 women would be prevented from dying from breast cancer for every woman overdiagnosed with invasive breast cancer or DCIS.